Adams Jennifer Athay, Chopski Nicole L, Adams Alex J
J Am Pharm Assoc (2003). 2023 Sep-Oct;63(5):1495-1499. doi: 10.1016/j.japh.2023.06.001. Epub 2023 Jun 7.
In December 2022, Congress passed the Mainstreaming Addiction Treatment Act, which removed the federal legal barrier to pharmacist buprenorphine prescribing. As a result, each state can now decide whether or not to allow pharmacists to prescribe buprenorphine as an additional access point to reduce fatal opioid overdoses. At least 10 states allow pharmacists to prescribe controlled substances under collaborative practice agreements. Two states (California and Idaho) have also created pathways for independent prescribing of buprenorphine by pharmacists. Additional states should seek to enable pharmacists to prescribe buprenorphine to increase access to a proven beneficial treatment and help reduce fatal opioid overdoses.
2022年12月，国会通过了《成瘾治疗主流化法案》，该法案消除了药剂师开具丁丙诺啡的联邦法律障碍。因此，现在每个州都可以决定是否允许药剂师开具丁丙诺啡，作为减少阿片类药物过量致死的额外途径。至少有10个州允许药剂师根据合作实践协议开具管制药品。有两个州（加利福尼亚州和爱达荷州）还为药剂师独立开具丁丙诺啡创造了途径。其他州应设法使药剂师能够开具丁丙诺啡，以增加获得经过验证的有益治疗的机会，并帮助减少阿片类药物过量致死情况。
